搭配診斷：全球市場展望（2011∼2021年） 是由出版商Visiongain在2011年08月所出版的。
這份英文市場調查報告書包含108 Pages 價格從美金2331起跳。
搭配診斷市場目前規模雖小，但預計今後將會是IVD市場中發展最快的區隔之一。而藥劑及診斷共用並非為新的概念，卻很快受到關注，醫療領域更往個別化醫療展開。與標靶治療組合之搭配診斷，為提供個別化醫療的工具之一。本市場受到對更安全、有效藥劑之需求增加帶動，今後將有絕大發展機會。
本報告為，探討搭配診斷市場現況及2011∼2021年銷售預測、地區別趨勢、新興商業模式、市場未滿足之需求、專家見解等，以下列摘要形式闡述。 封面圖片：
 第1章 實施概要
第2章 搭配診斷：簡介
- 治療範例之變化
- 何謂個別化醫療
- 體外診斷（IVD）及標靶治療：個別化醫療之中心
- 搭配診斷：個別化醫療之工具
- 搭配診斷所需之生物標誌
- 搭配診斷之發展
第3章 全球搭配診斷市場：2010∼2021年
- 範圍及極限
- 整體搭配診斷市場於2010年已達13億美金規模
- 搭配診斷之銷售預測：2010∼2015年
- 搭配診斷之銷售預測：2016∼2021年
- 搭配診斷將是IVD市場中發展最快的區隔之一
- 2010年之診斷與31.5％搭配診斷市場相關
- 診斷市場中極大之成長：2011∼2021年
第4章 搭配診斷之主要國家市場：2010∼2021年
第5章 搭配診斷市場之產品：已上市產品、產品線產品（2011年）
- 搭配診斷中已經開發之生物標誌物
- 搭配診斷市場：規模雖小但持續增加中
- 具有複雜法規途徑之市場
- 已上市之診斷方式：2011年
- 產品線搭配診斷
- 癌症為搭配診斷開發之主要適應症
第6章 搭配診斷市場環境：企業及合作（2010∼2021年）
- 概要
- 搭配診斷市場之利益關係人
- 促進搭配診斷開發之法規當局
- 測試機構
- 醫師、病患、治療判斷所需之更多資訊供應
- 診斷產品市場為製藥公司、診斷藥商製造機會
- 採用搭配診斷之優勢：製藥公司、診斷藥商展望
- 搭配診斷市場之企業
- 參與搭配診斷市場之企業驅力
- 搭配診斷市場之企業：產品開發及服務提供
- 搭配診斷開發之商業模式
- 幾乎所有製藥公司皆無診斷部門
- 製藥公司及合作：診斷藥商與Win-Win之關係
- Roche：搭配診斷所需之一站式服務
- Qiagen：合作模式擴大
- 搭配診斷開發所需之交易：2010∼2011年
第7章 SWOT分析
第8章 專家看法
第9章 結論
圖表
Abstract
Report Details
Our latest pharma report - Companion Diagnostics: World Market Outlook
2011-2021 - offers a comprehensive view of the global companion diagnostics
market. The report analyses recent trends in this market and anticipates the
progression in the market over the next decade with global, regional and
submarket forecasts. The report also reveals the market' s strengths and
weaknesses revealing areas that will experience growth and present new
business opportunities. Visiongain analyses predict the global value of the
companion diagnostics market in 2011 to be worth $1.57bn. A number of
specialty drugs will be associated with a companion diagnostic test by 2021,
increasing the global market for companion diagnostics.
Companion diagnostics are diagnostic tests that are linked to a particular
drug/therapy. This is a small, emerging market at present, but one of the
fastest growing segments in the IVD market. The concept of a drug-diagnostic
combination is not new, but has only started to garner interest, with the move
of healthcare towards personalised medicine. Companion diagnostics combined
with targeted therapeutics are the tools for providing personalised treatment.
This market has significant potential for growth with the increasing demand
for safer, efficacious drugs.
Visiongain' s research suggests that the world companion diagnostics market
will benefit from developments in biomarker discovery and use in early stages
of drug development. These biomarkers for disease can be developed into
companion diagnostics for clinical use. Also benefiting the companion
diagnostics market will be efforts on the part of the regulatory authorities
to develop clearer regulatory guidelines for the co-development of companion
diagnostics.
The Companion Diagnostics: World Market Outlook 2011-2021 report
examines the scope of growth available in the companion diagnostics industry
given the increasing cost of drug development, rising cost of healthcare, and
the need for medicines which do not have adverse drug reactions.
The companion diagnostics market is the fastest growing segment in the IVD
market. Visiongain predicts that this market will grow steadily to 2021. The
future of the companion diagnostics market appears promising, with increases
in the demand for high priced specialist therapies and the demand for safer,
more-efficacious drugs.
How will the companion diagnostic market develop this decade? Which regions
offer the most significant growth opportunities between 2011 and 2021? Which
of the companion diagnostic submarkets are growing most strongly? Who are the
leading companies in the companion diagnostics market? Which regions offer the
most significant companion diagnostics market growth opportunities between
2011 and 2021?
Visiongain answers these critical questions and many more through the in-depth
analyses that are presented in this report.
Detailed analysis of the global Companion Diagnostics Market
Companion Diagnostics: World Market Outlook 2011-2021 examines that sector
critically, through a comprehensive review of information sources, both
primary and secondary. This report provides detailed sales forecasts, market
share analyses, discussions of pipeline developments and analyses of
commercial drivers and restraints, including a SWOT analysis. There are 50
tables and figures included, as well as two full interviews with relevant
authorities. The result is a comprehensive market- and industry-centred study,
with detailed analyses and informed opinion to benefit your work.
Why you should buy Companion Diagnostics: World Market Outlook 2011-2021
In this report, you will receive the following benefits in particular:
- You will receive our assessment of the current market for companion
diagnostics
- You will discover sales trends for the overall companion diagnostics
market from 2011 to 2021 - seeing where commercial growth will occur
- You will discover sales trends for the main segment - theranostics - from
2011 to 2021 - with detailed discussions of market potential
- You will receive sales forecasts for leading geographical markets (US,
Japan, Germany, France, Italy, Spain, UK, China and India), with informed
discussion
- You will assess leading companies in the companion diagnostics market,
providing products and services in the market
- You will see a compiled list of some theranostic kits and lab tests that
are currently available in the market, and drug-diagnostic combinations in
development by pharmaceutical and diagnostic companies
- You will examine the emerging business models for the development of
companion diagnostics
- You will be able to investigate competition and opportunities influencing
the companion diagnostics market from 2011 onwards
- You will see what will stimulate and restrain the companion diagnostics
market from 2011
- You will discover the unmet needs in the market, driving the growth from
2011 onwards
- You will view expert opinion from our survey, including full interview
transcripts.
Table of Contents
1. Executive Summary
- 1.1 Companion Diagnostics Market Review
- 1.2 Aims, Scope and Format of the Report
- 1.3 Research and Analysis Methods
2. Introduction to Companion Diagnostics
- 2.1 Changing Paradigms of Treatment
- 2.2 What is Personalised Medicine?
- 2.3 In Vitro Diagnostics (IVD) and Targeted Therapies: The Core of
Personalised Medicine
- 2.3.1 What are In Vitro Diagnostic (IVD) Tests?
- 2.3.2 How IVDs Help Provide Personalised Treatment
- 2.4 Companion Diagnostics: Tools for Personalised Medicine
- 2.4.1 Theranostics: A Subset of Companion Diagnostics
- 2.5 Biomarkers to Companion Diagnostics
- 2.5.1 Genomic Biomarkers
- 2.5.2 Genomic Biomarkers in Oncology
- 2.6 Development of Companion Diagnostics
3. The World Companion Diagnostics Market, 2010-2021
- 3.1 Scope and Limitations
- 3.2 Total Companion Diagnostics Market was Worth $1.30bn in 2010
- 3.3 Sales Forecast for Total Companion Diagnostics Market, 2010-2015
- 3.4 Sales Forecast for Total Companion Diagnostics Market, 2016-2021
- 3.5 Companion Diagnostics is One of the Fastest Growing Segments in the
IVD Market
- 3.5.1 Companion Diagnostics Gaining Greater Share of the IVD Market
- 3.6 Theranostics Constituted 31.5% of the Companion Diagnostics Market in
2010
- 3.7 Strong Growth in the Theranostics Market, 2011-2021
- 3.7.1 Theranostics Gaining Greater Share of the Companion Diagnostics
Market, 2011-2021
4. Leading National Markets for Companion Diagnostics, 2010-2021
- 4.1 Leading National Markets for Companion Diagnostics, 2010
- 4.2 Leading National Markets for Companion Diagnostics: Sales Forecast,
2011-2021
- 4.2.1 The US Companion Diagnostics Market, 2011-2021
- 4.2.2 The Leading European Companion Diagnostics Markets, 2011-2021
- 4.2.3 The Japanese Companion Diagnostics Market, 2011-2021
- 4.2.4 Emerging-Economy Companion Diagnostics Markets
- 4.2.4.1 The Chinese Companion Diagnostics Market, 2011-2021
- 4.2.4.2 The Indian Companion Diagnostics Market, 2011-2021
5. Products in the Companion Diagnostics Market: Marketed and Pipeline, 2011
- 5.1 Biomarkers Being Developed into Companion Diagnostics
- 5.2 Market for Companion Diagnostics: Small, but Growing
- 5.3 A Complex Market with Multiple Regulatory Pathways
- 5.4 Marketed Theranostics, 2011
- 5.5 Pipeline Companion Diagnostics
- 5.6 Oncology is the Leading Indication for the Development of Companion
Diagnostics
6. Companion Diagnostics Market Landscape: Companies and Partnerships, 2010-2011
- 6.1 Overview
- 6.2 Stakeholders in the Companion Diagnostics Market
- 6.2.1 Regulatory Authorities Promoting the Development of Companion
Diagnostics
- 6.2.2 Testing Laboratories
- 6.2.3 Physicians and Patients: Need to be More Informed to Drive
Treatment Decisions
- 6.2.4 The Market for Theranostic Products is Creating Opportunities for
Pharmaceutical and Diagnostic Companies
- 6.3 Benefits of Employing Companion Diagnostics: Perspective of
Pharmaceutical and Diagnostic Companies
- 6.4 Companies in the Companion Diagnostics Market
- 6.4.1 Factors Driving Companies to Enter the Companion Diagnostics Market
- 6.4.2 Companies in the Companion Diagnostics Market: Developing Products
and Providing Services
- 6.5 Business Models for the Development of Companion Diagnostics
- 6.5.1 Few Pharmaceutical Companies Have Dedicated Diagnostics Units
- 6.5.2 Collaborating with Pharmaceuticals: A Win-Win for Diagnostic
Companies
- 6.5.3 Roche: A One Stop Shop for Companion Diagnostics
- 6.5.4 Qiagen: Growing on the Partnership Model
- 6.6 Deals for Development of Companion Diagnostics, 2010-2011
7. SWOT Analysis of the Companion Diagnostics Market
- 7.1 Introduction
- 7.2 Strengths and Weaknesses of the Sector
- 7.2.1 Maximising Benefits to Healthcare Stakeholders
- 7.2.2 Minimising Harm
- 7.2.3 Increasing Compliance
- 7.2.4 Streamlining Clinical Trials
- 7.2.5 Reviving Failed or Withdrawn Drugs
- 7.2.6 Reducing the Costs of Healthcare
- 7.2.7 Shifting From Reaction to Prevention
- 7.2.8 The Field of Diagnostics Has Traditionally Been an Undervalued
Area of Science When Compared to the Production of Pharmaceuticals
- 7.2.9 Perceived Lower Revenues and Higher Marketing Costs
- 7.3 Opportunities and Threats
- 7.3.1 Biomarkers: Translating into Companion Diagnostics
- 7.3.2 Reimbursement Challenges
- 7.3.3 Lack of Clear Regulatory Guidelines on Companion Diagnostics
- 7.3.4 Complex Business Models: Contradicting Objectives
- 7.3.5 Threat to the Blockbuster Model of Pharmaceutical Companies
8. Expert Opinion
- 8.1 Director from a Diagnostics Company in the Sector (Views Provided
Anonymously)
- 8.1.1 Most-Promising Therapeutic Areas for IVD
- 8.1.2 Unmet Medical Needs in IVD
- 8.1.3 Greatest Obstacles to Market Growth
- 8.1.4 Prospects for IVD Market Growth in Developing Countries
- 8.1.5 Prospects for Theranostics
- 8.2 Interview with Herbie Newell, Professor of Cancer Therapeutics,
Northern Institute for Cancer Research, University of Newcastle, UK
- 8.2.1 The Importance of Biomarkers for Cancer Therapy
- 8.2.2 Technological Platforms Used in the Discovery of Novel Biomarkers
- 8.2.3 The Challenges of Translating Cancer Biomarker Discoveries to the
Clinic
- 8.2.4 Cancer Heterogeneity and Targeted Therapy
- 8.2.5 Reform in Pharmaceutical R&D and the Importance of Public-Private
Partnerships
- 8.2.6 Current Trends and the Future of Cancer Research
- 8.3 Vice President, Diagnostics Division of a Global Pharmaceutical
Company (Views Provided Anonymously)
- 8.3.1 Definition of Companion Diagnostics
- 8.3.2 Pharmaceutical Company and Companion Diagnostics Market
- 8.3.3 Drivers and Restraints for Companion Diagnostics Market
- 8.3.4 Most Promising Therapeutic Areas for Development of Companion
Diagnostic Tests
- 8.3.5 Recent Trends in the Companion Diagnostics Market and Future Growth
9. Conclusions
- 9.1 Overview
- 9.2 Prominent Companies in the Market
- 9.3 Commercial Drivers of the Companion Diagnostics Market
- 9.4 Pharmacogenomics: Driving the Personalised Medicine Approach
- 9.5 Personalised Medicine is a Strong Driver of the Theranostics Sector
- 9.6 Commercial Restraints in the Companion Diagnostics Market
- 9.7 Targeted Therapies Will Revolutionise the Current Model of
Pharmaceutical R&D
- 9.8 Future Outlook and Concluding Remarks
Appendix A
Appendix B
Visiongain report evaluation form
List of Tables
- Table 2.1 Differences between Traditional & Personalised Medicine, 2011
- Table 2.2 Examples of Clinically Relevant Cancer Biomarkers, 2011
- Table 3.1 World Companion Diagnostics Market: Sales ($bn) and Market Share
(%), 2010
- Table 3.2 Total Companion Diagnostics Market: Sales Forecast ($bn),
2010-2021
- Table 3.3 Market Shares (%) of Companion Diagnostics in the IVD Market,
2010, 2015 & 2021
- Table 3.4 World Theranostics Market: Sales ($bn) and Market Share (%), 2010
- Table 3.5 World Theranostics Market: Sales Forecast ($bn), 2010-2021
- Table 3.6 Market Shares (%) of Theranostics in the Companion Diagnostics
Market, 2010, 2015 & 2021
- Table 4.1 Leading National Markets for Companion Diagnostics ($m), 2010
- Table 4.2 Leading Companion Diagnostics National Market Forecasts ($m),
2010-2021
- Table 4.3 Leading National Markets: Market Shares (%), 2010, 2015 & 2021
- Table 4.4 The US Companion Diagnostics Market Forecast ($m), 2010-2021
- Table 4.5 The EU5 Companion Diagnostics Market Forecasts ($m), 2010-2021
- Table 4.6 The Japanese Companion Diagnostics Market Forecast ($m),
2010-2021
- Table 4.7 The Chinese and Indian Companion Diagnostics Market Forecasts
($m), 2010-2021
- Table 5.1 List of Biomarkers: Testing Required Prior to Prescription, 2011
- Table 5.2 List of Biomarkers: Testing Recommended/For Information Only in
Drug Label, FDA, 2011
- Table 5.3 List of Some Marketed Theranostics, 2011
- Table 5.4 Development Pipeline: Drug-Diagnostic Combinations, 2011
- Table 6.1 Growth of Companion Diagnostics: Benefits for Pharmaceutical and
Diagnostic Companies, 2011
- Table 6.2 List of Some Companies in the Companion Diagnostics Market, 2011
- Table 6.3 Qiagen Sales ($m), 2010
- Table 6.4 Some Companion Diagnostic Deals, 2010
- Table 6.5 Some Companion Diagnostic Deals, 2011
- Table 7.1 SWOT Analysis of the Companion Diagnostics Market, 2011-2021
- Table 7.2 Average Response Rates to Treatment for Various Diseases, 2010
- Table 7.3 Drugs Metabolised by CYP450: 2C19 and 2D6, 2011
- Table 9.1 Companion Diagnostics Market: World Sales Forecast ($bn), 2010,
2012, 2015, 2018, and 2021
List of Figures
- Figure 2.1 The Pillars of Personalised Medicine
- Figure 2.2 Type of Companion Diagnostics on the Basis of Purpose/Use, 2011
- Figure 2.3 Development of Biomarkers into Companion Diagnostics, 2011
- Figure 3.1 World Companion Diagnostics Market Share (%) in the IVD Market,
2010
- Figure 3.2 World Companion Diagnostics Market: Sales Forecast ($bn),
2010-2021
- Figure 3.3 World Companion Diagnostics Market Share (%) in the IVD Market,
2015
- Figure 3.4 World Companion Diagnostics Market Share (%) in the IVD Market,
2021
- Figure 3.5 World Theranostics Market Share (%) in the Companion
Diagnostics Market, 2010
- Figure 3.6 World Companion Diagnostics Sub-Markets: Sales Forecasts ($bn),
2010-2021
- Figure 3.7 World Theranostics Market Share (%) in the Companion
Diagnostics Market, 2015
- Figure 3.8 World Theranostics Market Share (%) in the Companion
Diagnostics Market, 2021
- Figure 4.1 Companion Diagnostics Market Shares (%) in Leading National
Markets, 2010
- Figure 4.2 Companion Diagnostics Market Shares (%) in Leading National
Markets, 2015
- Figure 4.3 Companion Diagnostics Market Shares (%) in Leading National
Markets, 2021
- Figure 4.4 The US Companion Diagnostics Market Forecast ($m), 2010-2021
- Figure 4.5 The EU5 Companion Diagnostics Market Forecasts ($m), 2010-2021
- Figure 4.6 The Japanese Companion Diagnostics Market Forecast ($m),
2010-2021
- Figure 4.7 The Chinese and Indian Companion Diagnostics Market Forecasts
($m), 2010-2021
- Figure 6.1 Stakeholders in the Companion Diagnostics Market, 2011
- Figure 6.2 Business Models for Development of Companion Diagnostics, 2011
- Figure 7.1 Average Response Rates for Various Diseases, 2010
- Figure 9.1 Companion Diagnostics Market: World Sales Forecast ($bn), 2010,
2012, 2015, 2018, and 2021
Companies Listed
- 20/20 GeneSystems
- A&G Pharmaceutical
- Abbott Laboratories
- Abbott Molecular
- Abkine Pharmaceuticals
- Advanced Cell Diagnostics
- Aeterna Zentaris
- Aetna
- Agendia
- Alacris Theranostics
- Alere
- Allegro Diagnostics
- Almac Group
- AltheaDx
- Amgen
- Amoy Diagnostics Company
- Anthem
- Ariad Pharmaceuticals
- Array BioPharma
- AssuerRx Health
- AstraZeneca
- Asuragen
- Aureon Laboratories
- AutoGenomics
- Bayer Schering Pharma
- Beckman Coulter
- Biocartis
- Biocrates Life Sciences
- Biodesix
- Biogen Idec
- BioGenex Laboratories
- BioMarin Pharmaceuticals
- Biomarker Strategies
- Biomedical Diagnostics (BMD)
- bioMerieux
- Biomonitor
- Biotage
- bioTheranostics
- Boehringer Ingelheim
- Brain Resource Company
- Bristol-Myers Squibb
- Cancer Research Technology Limited (CRT)
- CancerGuide Diagnostics
- Caprion Proteomics
- Caris Life Sciences
- Celera Corporation
- Celgene Corporation
- Centers for Medicare and Medicaid Services (CMS)
- Cephalon
- Cepheid
- Cigna Corporation
- Clavis Pharma
- Clinical Reference Laboratory
- Clovis Oncology
- CompanDx
- Crescendo Bioscience
- Curidium Medica
- Dako
- Debiopharm Group
- DiagnoCure
- Dx assays
- DxS
- Eisai
- Eli Lilly and Company
- Endocyte
- ERYtech Pharma
- European Medicines Agency (EMA)
- Exosome Diagnostics
- Flagship Biosciences
- Foundation Medicine
- Genfit
- GenMark Diagnostics
- Genomic Health
- Genzyme Genetics
- GlaxoSmithKline
- Hatteras Venture Partners
- Health Net
- HistologiX
- Hoffmann-La Roche
- Hologic
- Humana
- ImClone Systems
- InDex Pharmaceuticals
- Intersouth Partners
- Inverness Medical Innovations
- Invivoscribe Technologies
- Ipsen
- Ipsogen
- Janssen Pharmaceutica
- Johnson & Johnson
- Kaiser Permanente
- Kimball Genetics
- Laboratory Corporation of America (LabCorp)
- Laboratory for Personalized Molecular Medicine
- Life Technologies Corporation
- M.D. Anderson Cancer Center
- MDxHealth
- Merck KGaA
- Merck Serono
- MolecularMD
- Monogram Biosciences
- Myriad Genetics
- Nanosphere
- Neovacs
- Newcastle University (UK)
- Novartis Pharmaceuticals Corporation
- Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)
- Oxford BioTherapeutics
- Oxford Genome Sciences
- Pfizer
- Progenika Biopharma
- Prometheus Laboratories
- Psynova Neurotech
- Qiagen
- Quest Diagnostics
- Quintiles Transnational Corporation
- Randox Pharma Services
- RiboMed Biotechnologies
- Roche Molecular Systems
- Rules-Based Medicine
- Saladax Biomedical
- Sanofi
- Signal Genetics
- Signature Diagnostics
- Sirius Genomics
- Skyline Diagnostics
- Target Discovery
- TcLand Expression
- Telegraph Hill Partners
- The Netherlands Cancer Institute (NKI)
- Theranostics (NZ)
- Theranostics Health
- Third Wave Technologies
- TIB MolBiol
- Tragara Pharmaceuticals
- Transgene
- Transgenomic
- TrimGen Corporation
- Tufts Center for the Study of Drug Development
- Unilabs
- United HealthCare Services
- US Food and Drug Administration (FDA)
- US National Institutes of Health (NIH)
- Ventana Medical Systems
- Veridex
- Weisenthal Cancer Group
- WellPoint
|
